Skip to main content

Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations

Trial Status: Active

This phase II trial studies how well pemigatinib works in treating patients with colorectal cancer with mutations (alterations) in a FGFR gene and that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Pemigatinib may stop the growth of tumor cells by blocking FGFR, which is needed for cell growth.

Inclusion Criteria

  • Registered to Colorectal and Liquid Biopsy Molecularly Assigned Therapy (COLOMATE) Academic and Community Cancer Research United (ACCRU)-GI-1611 and: * COLOMATE Companion Trial Recommendation Form indicates patient qualifies to be screened for a COLOMATE companion trial * COLOMATE Companion Trial Recommendation Form date of completion is =< 30 days prior to registration
  • Histologically or cytologically confirmed diagnosis of metastatic or unresectable colorectal cancer (mCRC), based on documentation from local or outside review of pathology according to each site’s established institutional procedure
  • Documentation of an activating genomic alteration(s) in FGF/FGFR1-3 (gain of function mutations, translocations, and amplifications allowed) in tumor tissue or blood tested at a Clinical Laboratory Improvement Amendments (CLIA) – certified laboratory
  • Provide informed written consent
  • Patient must have received and progressed on, or be intolerant to, each of the following treatments for mCRC (or have contraindication to these treatments): * Fluoropyrimidine * Oxaliplatin * Irinotecan * Pembrolizumab * Nivolumab * Anti-VEGF (vascular endothelial growth factor) monoclonal antibody, if eligible for this therapy * Anti-EGFR (epidermal growth factor receptor) monoclonal antibody, if eligible for this therapy
  • Measurable disease
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2
  • Absolute neutrophil count (ANC) >= 1500/mm^3 (obtained =< 28 days prior to registration)
  • Platelet count >= 100,000/mm^3 (obtained =< 28 days prior to registration)
  • Hemoglobin >= 9.0 g/dL (obtained =< 28 days prior to registration)
  • Total bilirubin =< 1.5x upper limit of normal (ULN), or =< 2.5x ULN if patient has Gilbert syndrome or disease involving the liver (obtained =< 28 days prior to registration)
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5x ULN (or =< 5x ULN in presence of suspected liver metastases) (obtained =< 28 days prior to registration)
  • Serum phosphate < institutional ULN (obtained =< 28 days prior to registration)
  • Serum calcium within institutional normal range, or serum albumin-corrected calcium within institutional normal range (if serum albumin is outside of the institutional normal range) (obtained =< 28 days prior to registration)
  • Potassium levels > institutional lower limit of normal (supplementation can be used to correct potassium level during screening) (obtained =< 28 days prior to registration)
  • Serum creatinine =< 1.5x ULN, or calculated creatinine clearance > 30 mL/min using the Cockcroft-Gault formula or 24-hours urine collection analysis (obtained =< 28 days prior to registration)
  • Corrected QT interval (QTc) by Fridericia’s method (QTcF) assessed by electrocardiogram (ECG) completed =< 28 days prior to registration, and resulted as: * QTcF =< 450 msec in men, or * QTcF =< 470 msec in women
  • Negative serum pregnancy test completed =< 7 days prior to registration, for women of childbearing potential only
  • Willing to provide tissue and blood samples for correlative research purposes
  • Willing to allow transfer of tissue and blood samples, clinical information, and outcome data collected from this trial for future research

Exclusion Criteria

  • Prior treatment with pemigatinib
  • Prior treatment with a selective FGFR inhibitor =< 180 days (6 months) prior to registration
  • Known hypersensitivity or severe reaction to an FGFR inhibitor, or to the excipients of pemigatinib (i.e. microcrystalline cellulose, sodium starch glycolate, and magnesium stearate)
  • Current evidence of clinically significant corneal or retinal disorder confirmed by ophthalmologic examination
  • Treatment with other investigational study drug for any indication for any reason, or receipt of anticancer medications =< 14 days prior to registration
  • Major surgery =< 28 days prior to registration
  • External beam radiation therapy =< 28 days prior to registration, or palliative radiation for non-central nervous system (CNS) disease =< 14 days prior to registration
  • Brain metastases, central nervous system (CNS) metastases, leptomeningeal disease, or spinal cord compression * NOTE: Patients who are asymptomatic or previously treated and stable, without evidence of progression for >= 28 days prior to registration are eligible * NOTE: Patients taking concomitant corticosteroids and/or anticonvulsants are allowed if patient is on a stable or decreasing dose of such treatment for >= 28 days prior to registration
  • History or presence of significant cardiovascular disease or condition including: * Uncontrolled angina pectoris (Canadian Cardiovascular Society grade II-IV despite medical therapy) * Congestive heart failure (New York Heart Association class III or IV) * Uncontrolled arrhythmia requiring therapy. Note: Patients with a pacemaker and well-controlled rhythm for >= 28 days prior to registration are not excluded * Any of the following occurring =< 6 months prior to registration: myocardial infarction, angioplasty, cardiac stenting, coronary/peripheral artery bypass graft, cerebrovascular accident or transient ischemic attack
  • Failure to adequately recover (i.e. to =< grade 1 [according to Common Terminology Criteria for Adverse Events (CTCAE) version (v.)5] or to pre-treatment baseline) from adverse events (AEs) deemed by the investigator as clinically significant and attributed to prior therapy. Exception: alopecia
  • Current use of prohibited medication
  • Use of any potent CYP3A4 inhibitors or inducers or moderate CYP3A4 inducers =< 14 days or 5 half-lives (whichever is shorter) prior to registration. Note: topical ketoconazole will be allowed
  • History of hypovitaminosis D requiring supraphysiologic doses to replenish the deficiency. Note: patients receiving vitamin D food supplements are allowed
  • History and/or current evidence of ectopic mineralization/calcification, including but not limited to soft tissue, kidneys, intestine, myocardia, or lung; with the exception of calcified lymph nodes and asymptomatic arterial or cartilage/tendon calcification
  • Unable or unwilling to swallow pemigatinib and keep a medication diary, or significant gastrointestinal disorder(s) that could interfere with absorption, metabolism or excretion of pemigatinib per the discretion of the investigator
  • Any of the following because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown: * Pregnant women * Nursing women * Women of childbearing potential or men able to father children who have a female partner of childbearing potential, who are unwilling to employ acceptable contraception
  • Known history of human immunodeficiency (HIV) infection or positivity on immunoassay confirmed per local standards * Note: HIV test is not required for screening, but patients with a known history of HIV infection will be excluded
  • Evidence of active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
  • Other known active malignancy =< 5 years prior to registration * EXCEPTIONS: Non-melanotic skin cancer or carcinoma in situ of the cervix, provided there is no known active disease and no additional therapy for the condition is ongoing or required during the trial period * NOTE: anti-estrogen/androgen therapy or bisphosphonates allowed
  • Co-morbid systemic illness, other severe concurrent disease, or psychiatric illness/social situation which, in the judgment of the investigator, would make the patient inappropriate for entry into this study, limit compliance with study requirements, or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimen


Mayo Clinic in Arizona
Status: ACTIVE
Contact: Laurie Ann Mihalik
Phone: 480-342-6140

District of Columbia

MedStar Georgetown University Hospital
Contact: Brenton Foretich
Phone: 202-687-4346


Emory University Hospital / Winship Cancer Institute
Contact: Kim Nguyen
Phone: 404-778-5680


University of Chicago Comprehensive Cancer Center
Contact: Heather Macauley
Phone: 773-702-9251


Mayo Clinic in Rochester
Status: ACTIVE
Contact: Joleen M. Hubbard


Saint Louis
Washington University School of Medicine
Contact: Jesse A. Huffman
Phone: 314-747-6268

North Carolina

Duke University Medical Center
Status: ACTIVE
Contact: Terrance Lawrence
Phone: 919-668-1861


Vanderbilt University / Ingram Cancer Center
Status: ACTIVE
Contact: Jennifer Gray Whisenant
Phone: 615-875-8630


Aurora Cancer Care-Milwaukee West
Contact: Jennifer Mathieu
Phone: 414-302-2312


I. To assess overall response rate (ORR) of pemigatinib in patients with metastatic or unresectable colorectal cancer harboring activating FGFR alterations.


I. To assess the clinical benefit rate (complete response + partial response + stable disease) with pemigatinib.

II. To assess progression free survival (PFS) and overall survival (OS) with pemigatinib.

III. Assess changes in patient quality of life (QOL) as measured by the linear analogue self-assessment (LASA) questionnaire.

IV. Assess the frequency and severity of adverse events.


I. To assess plasma pharmacodynamic biomarkers of response and resistance to therapy.

II. To explore any correlation between tissue and blood based biomarkers and clinical outcomes.


Patients receive pemigatinib orally (PO) once daily (QD) on days 1-21. Treatment repeats every 21 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for 3 years after registration.

Trial Phase Phase II

Trial Type Treatment

Lead Organization
Academic and Community Cancer Research United

Principal Investigator
Kristen Keon Ciombor

  • Primary ID ACCRU-GI-1701
  • Secondary IDs NCI-2019-05877
  • ID NCT04096417